Discussing Lower-Risk MDS Treatment Options With Dr. Stahl

By Blood Cancer Talks - Last Updated: September 5, 2024

In this episode of “Blood Cancer Talks,” hosts Ashwin Kishtagari, MD, and Edward Cliff, MD, are joined by guest Maximilian Stahl, MD, of the Dana-Farber Cancer Institute, to discuss imetelstat and luspatercept for the treatment of lower-risk myelodysplastic syndromes (MDS).

The episode discusses the following trials:

MEDALIST trial (luspatercept vs placebo)
COMMANDS trial (luspatercept vs epoetin alfa)
IMerge trial (imetelstat vs placebo)

This podcast originally appeared on Blood Cancer Talks.

Dr. Schmidt on Quadruplet Therapy for Newly Diagnosed, Transplant Ineligible MM

Dr. Gerds on the Treatment of Polycythemia Vera

Dr. Iacoboni Highlights Key Lymphoma Abstracts Presented This Year

MRD Use in Multiple Myeloma: Clinical Practice, Clinical Trials, and Drug Approval

Dr. Tefferi on Recent Ruxolitinib Combination Trials for Myelofibrosis

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

Discussing Lower-Risk MDS Treatment Options With Dr. Stahl

Related